Minkow Emily 4
4 · Prevail Therapeutics Inc. · Filed Mar 11, 2020
Insider Transaction Report
Form 4
Minkow Emily
Chief Business Officer
Transactions
- Exercise/Conversion
Common Stock
2019-12-24$0.18/sh+13,000$2,340→ 13,000 total - Exercise/Conversion
Stock Option (Right to Buy)
2019-12-24−13,000→ 149,000 totalExercise: $0.18Exp: 2027-10-24→ Common Stock (13,000 underlying)
Footnotes (1)
- [F1]25% of the total number of shares underlying the option vested and became exercisable on November 6, 2018 and an additional 1/48th of the total number of shares underlying the option vests and becomes exercisable on the first day of each of the thirty-six (36) consecutive months thereafter subject, in all cases, to the Reporting Person providing continuous service with the Issuer on each such date.